

[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES

Publication number: WO0017201

Publication date: 2000-03-30

Inventor: SHIMADA JUNICHI (JP); IMMA HIRONORI (JP); OSAKADA NAO TO (JP); SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP)

Applicant: KYOWA HAKKO KOGYO KK (JP); SHIMADA JUNICHI (JP); IMMA HIRONORI (JP); OSAKADA NAO TO (JP); SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP)

Classification:

- **International:** A61P25/24; A61P25/28; C07D487/04; A61P25/00; C07D487/00; (IPC1-7): C07D487/04; A61K31/505

- **European:** C07D487/04

Application number: WO1999JP05176 19990922

Priority number(s): JP19980267178 19980922

Also published as:

EP1116722 (A1)
US6545000 (B1)
EP1116722 (A4)
CA2344828 (A1)
EP1116722 (B1)
DE69923197T (T2)
AU756144B (B2)

[less <<](#)

Cited documents:

WO9842711
US5270311

[Report a data error here](#)

Abstract of WO0017201

[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by general formula (I) or pharmacologically acceptable salts thereof which show adenosine A2A receptor antagonism, wherein R<1> represents heteroaryl, etc.; R<2> represents hydrogen, etc.; na and nb represent each an integer of 0 to 4; Q represents hydrogen, etc.; R<6> represents hydrogen, etc.; R<3> represents (i) hydroxy, (ii) hydroxy (lower alkyl), (iii) lower alkoxy, or (iv) imidazo[1,2-a]pyridyl, etc.; and R<4> and R<5> represent each lower alkyl or aryl, or R<4> and R<5> form together with the adjacent carbon atom a saturated carbon ring when R<3> is any of (i) to (iii); or R<4> and R<5> represent each hydrogen, lower alkyl or aryl, or R<4> and R<5> form together with the adjacent carbon atom a saturated carbon ring when R<3> is (iv).

Data supplied from the **esp@cenet** database - Worldwide